N
Nuvectis Pharma, Inc.
NVCTCIK 0001875558NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-26.44M
Total Assets
$31.71M
Equity
$18.41M
Shares Out
26.49M
Op. Cash Flow
$-16.01M
Business
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company that develops innovative precision medicines for serious oncology indications. It advances product candidates through discovery, preclinical work and clinical trials, with lead programs NXP800, a GCN2-activating small molecule, and NXP900, a targeted SRC/YES1 kinase inhibitor. Its business comprises clinical development programs, licensing and collaboration arrangements, intellectual property management and regulatory strategy. Nuvectis pursues global development and potential commercialization through clinical trial networks, investigator-sponsored studies, academic collaborations and third-party contract research organizations and manufacturers across multiple jurisdictions.
Summary from filing dated 2025-02-25
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 18 | 13 | 15 | 13 | 10 | |
| General and administrative | 9 | 7 | 8 | 6 | 3 | |
| OPERATING LOSS | −28 | −20 | −23 | −19 | −13 | |
| Finance income | 1 | 847,000 | 637,000 | 149,000 | 4,000 | |
| NET LOSS | −26 | −19 | −22 | −19 | −13 | |
| EFFECT OF WARRANTS MODIFICATION, see Note 6 | −2 | — | — | — | — | |
| TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | −29 | −19 | −22 | −19 | −13 | |
| BASIC NET LOSS PER COMMON SHARE OUTSTANDING, see Note 8 | −1.32 | −1.11 | −1.43 | −1.51 | −3.02 | |
| DILUTED NET LOSS PER COMMON SHARE OUTSTANDING, see Note 8 | −1.32 | −1.11 | −1.43 | −1.51 | −3.02 | |
| Basic weighted average number of common shares outstanding | 22 | 17 | 16 | 13 | 4 | |
| Diluted weighted average number of common shares outstanding | 22 | 17 | 16 | 13 | 4 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 32 | 19 | 19 | 20 | 6 | |
| Other current assets | 75,000 | 74,000 | 59,000 | 412,000 | 91,000 | |
| TOTAL CURRENT ASSETS | 32 | 19 | 19 | 20 | 6 | |
| TOTAL ASSETS | 32 | 19 | 19 | 20 | 7 | |
| Accounts payables | 6 | 2 | 3 | 3 | 1 | |
| Accrued liabilities | 115,000 | 840,000 | 415,000 | 445,000 | 395,000 | |
| Employee compensation and benefits | 7 | 6 | 4 | 2 | 142,000 | |
| TOTAL CURRENT LIABILITIES | 13 | 9 | 7 | 6 | 2 | |
| TOTAL LIABILITIES | 13 | 9 | 7 | 6 | 2 | |
| COMMITMENTS AND CONTINGENCIES, see Note 3 | — | — | — | — | — | |
| Common Shares, $0.00001 par value - 60,000,000 shares authorized as of December 31, 2025, and December 31, 2024, 25,676,798, and 19,495,683 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | — | — | — | — | |
| Additional paid in capital | 118 | 83 | 66 | 46 | 2 | |
| Accumulated deficit | −100 | −73 | −54 | −32 | −13 | |
| TOTAL SHAREHOLDERS' EQUITY | 18 | 10 | 12 | 14 | −11 | |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 32 | 19 | 19 | 20 | 7 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −26 | −19 | −22 | −19 | −13 | |
| Cost of share-based payments | 6 | 5 | 5 | 2 | 2 | |
| Increase in other current assets | −1,000 | −15,000 | 353,000 | −321,000 | −91,000 | |
| Increase/(decrease) in accounts payable | 4 | −273,000 | −139,000 | 2 | — | |
| (Decrease)/increase in accrued liabilities | −725,000 | 425,000 | −30,000 | 338,000 | — | |
| Increase in employee compensation and benefits | 1 | 2 | 1 | 2 | — | |
| Net cash used in operating activities | −16 | −12 | −16 | −14 | −10 | |
| Net cash provided by (used in) investing activities | — | — | 0 | 0 | — | |
| Net cash provided by financing activities | 29 | 12 | 15 | 28 | 15 | |
| INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS | 13 | −593,000 | −867,000 | 14 | 6 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro